Edition:
United States

Orexigen Therapeutics Inc (OREX.OQ)

OREX.OQ on NASDAQ Stock Exchange Global Select Market

1.26USD
13 Dec 2017
Change (% chg)

$-0.04 (-3.08%)
Prev Close
$1.30
Open
$1.30
Day's High
$1.30
Day's Low
$1.26
Volume
75,656
Avg. Vol
30,367
52-wk High
$5.69
52-wk Low
$1.26

Latest Key Developments (Source: Significant Developments)

Man Group Plc Reports 8.54 Pct Passive Stake In Orexigen Therapeutics
Friday, 1 Dec 2017 12:06pm EST 

Dec 1 (Reuters) - Orexigen Therapeutics Inc ::MAN GROUP PLC REPORTS 8.54 PERCENT PASSIVE STAKE IN OREXIGEN THERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING‍​.  Full Article

Orexigen Says Entered Into Exchange Agreements With Holders
Friday, 1 Dec 2017 06:23am EST 

Dec 1 (Reuters) - Orexigen Therapeutics Inc ::OREXIGEN - ENTERED INTO EXCHANGE AGREEMENTS WITH HOLDERS OF 2.75% CONVERTIBLE EXCHANGE SENIOR NOTES DUE 2020, 2.75% CONVERTIBLE SENIOR NOTES DUE 2020.OREXIGEN THERAPEUTICS- AGREED TO ISSUE AGGREGATE OF 2.1 MILLION SHARES OF STOCK, IN EXCHANGE FOR ABOUT $6.5 MILLION IN AGGREGATE PRINCIPAL AMOUNT OF NOTES.  Full Article

Orexigen Therapeutics Q3 loss per share $1.35
Monday, 13 Nov 2017 04:01pm EST 

Nov 13 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics announces third quarter 2017 financial results.Q3 loss per share $1.35.Q3 revenue $18.9 million.  Full Article

Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt
Monday, 13 Nov 2017 08:08am EST 

Nov 13 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt, Germany for contrave in Latin America.Orexigen Therapeutics - ‍Orexigen will receive an upfront payment and other potential regulatory and sales milestones, which have not been disclosed​.Orexigen Therapeutics Inc - ‍merck KGaA, Darmstadt, Germany will be responsible for all commercialization and regulatory activities ​.Orexigen Therapeutics Inc - ‍Orexigen will also be responsible for product supply​.Orexigen Therapeutics Inc - ‍under terms of agreement, Merck KGaA, Darmstadt, Germany will own marketing authorization in region​.  Full Article

Orexigen Therapeutics - pursuing potential actions including merger or sale of co
Monday, 16 Oct 2017 06:27am EDT 

Oct 16 (Reuters) - Orexigen Therapeutics Inc :Orexigen Therapeutics Inc says ‍expects total revenues for Q3 of 2017 to be between about $18.1 million and $19.1 million-SEC filing​.Orexigen Therapeutics-‍management evaluating whether there are relevant conditions to raise substantial doubt about co's ability to continue as going concern​.Orexigen Therapeutics-in connection with evaluation, ‍co currently pursuing number of potential actions, including attempting to pursue merger or sale of co.  Full Article

Orexigen announces favorable decision from U.S. court in patent litigation, confirming exclusivity for Contrave through 2030
Friday, 13 Oct 2017 02:40pm EDT 

Oct 13 (Reuters) - Orexigen Therapeutics Inc ::Orexigen announces favorable decision from U.S. District Court in patent litigation, confirming exclusivity for Contrave through 2030.Orexigen therapeutics - U.S. Court issued ruling in favor of Orexigen in litigation against Actavis Laboratories FL inc for three patents for Contrave​.  Full Article

Valeant acquires Canadian rights for Contrave in treatment of obesity
Tuesday, 30 Aug 2016 08:00am EDT 

Valeant Pharmaceuticals International Inc : Valeant acquires the Canadian rights for Contrave® in the treatment of obesity . Valeant expects to file with health Canada for regulatory approval by January 2017 . Valeant will be responsible for obtaining Canadian regulatory approval and for all commercialization activities and expenses . Says Orexigen and Valeant anticipate launching Mysimba in 11 countries in Q4 of 2016 .Orexigen and Valeant anticipate launching Mysimba in 2 countries, in addition to 11 countries, in Q1 of 2017.  Full Article

Orexigen Therapeutics announces commercialization and distributorship agreement with Valeant Canada for Contrave
Tuesday, 30 Aug 2016 08:00am EDT 

Orexigen Therapeutics Inc :Orexigen Therapeutics announces commercialization and distributorship agreement with Valeant Canada for Contrave® (naltrexone hcl / bupropion hcl extended release).  Full Article

Orexigen Therapeutics announces Q2 loss per share $1.73
Thursday, 4 Aug 2016 04:01pm EDT 

Orexigen Therapeutics Inc : Orexigen Therapeutics reports business and financial results for the second quarter ended June 30, 2016 . Q2 revenue $7.8 million versus I/B/E/S view $6.9 million . Q2 loss per share $1.73 .Q2 earnings per share view $-1.47 -- Thomson Reuters I/B/E/S.  Full Article

Orexigen Therapeutics unit, ROVI announce agreement
Monday, 1 Aug 2016 08:30am EDT 

Orexigen Therapeutics Inc : "Expect mysimba to contribute to group's revenue in next few years" . Unit, Laboratorios Farmacéuticos Rovi S.A. executed commercialization and distributorship agreement for mysimba .Rovi expects to begin marketing mysimba by year-end 2016.  Full Article

BRIEF-Man Group Plc Reports 8.54 Pct Passive Stake In Orexigen Therapeutics

* MAN GROUP PLC REPORTS 8.54 PERCENT PASSIVE STAKE IN OREXIGEN THERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING‍​ Source text : http://bit.ly/2AKRpMo Further company coverage: